Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR T Cells in Multiple Myeloma
NCT03602612Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial in multiple myeloma (MM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicity at 28 days. Started Sep 2018; status: completed.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03602612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602612.